Prospective randomized phase II trial with gemcitabine plus sunitinib versus gemcitabine alone in first-line therapy of metastatic or locally advanced pancreatic cancer.
Phase of Trial: Phase II
Latest Information Update: 05 Nov 2014
At a glance
- Drugs Gemcitabine (Primary) ; Sunitinib (Primary)
- Indications Pancreatic cancer
- Focus Therapeutic Use
- Acronyms CESAR
- 04 Jun 2013 Primary endpoint 'Progression-free-survival-duration' has not been met according to results presented at the 49th Annual Meeting of the American Society of Clinical Oncology.
- 30 Nov 2011 Actual end date Nov 2011 added as reported by ClinicalTrials.gov.
- 30 Nov 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.